Journal of Nutrition and Metabolism

Journal of Nutrition and Metabolism / 2012 / Article
Special Issue

Change in Nutrition and Lifestyle in the Eastern Mediterranean Region: Health Impact

View this Special Issue

Review Article | Open Access

Volume 2012 |Article ID 109037 |

Akl C. Fahed, Abdul-Karim M. El-Hage-Sleiman, Theresa I. Farhat, Georges M. Nemer, "Diet, Genetics, and Disease: A Focus on the Middle East and North Africa Region", Journal of Nutrition and Metabolism, vol. 2012, Article ID 109037, 19 pages, 2012.

Diet, Genetics, and Disease: A Focus on the Middle East and North Africa Region

Academic Editor: Hamed R. Takruri
Received31 Aug 2011
Accepted27 Nov 2011
Published29 Mar 2012


The Middle East and North Africa (MENA) region suffers a drastic change from a traditional diet to an industrialized diet. This has led to an unparalleled increase in the prevalence of chronic diseases. This review discusses the role of nutritional genomics, or the dietary signature, in these dietary and disease changes in the MENA. The diet-genetics-disease relation is discussed in detail. Selected disease categories in the MENA are discussed starting with a review of their epidemiology in the different MENA countries, followed by an examination of the known genetic factors that have been reported in the disease discussed, whether inside or outside the MENA. Several diet-genetics-disease relationships in the MENA may be contributing to the increased prevalence of civilization disorders of metabolism and micronutrient deficiencies. Future research in the field of nutritional genomics in the MENA is needed to better define these relationships.

1. Introduction

Over the past few decades, the MENA has been witnessing significant changes in food habits paralleled by an important preponderance of metabolite-related diseases. In a region whose traditional diet is known to be healthy due to high vegetable proteins, fibers, minerals, and vitamins with low content of unfavorable food products, the “industrialization/westernization of the diet” is a well-studied and documented phenomenon [13]. The MENA has been losing its traditional diet which was distinguished by its diversity and richness in raw foods, proteins, and multivitamins, in the favor of a more industrial diet which consists of increased preprocessed foods, sugars, fats, alcohol, animal products, saturated- and trans-fatty acids, and relatively less vitamins and minerals with decreased consumption of milk, fruits, and vegetables [4]. A big part of this change is attributed to the lifestyle changes and globalization with the invasion of western fast food to the MENA countries. Dietary choices, minimum physical activity, religious habits, consumer ignorance, high population growth rates, economic factors, and lack of both protection laws and food fortification programs are other critical factors that influence the nutritional status in the region [5]. These changes in dietary and lifestyle patterns contribute to an increase in the rates of micronutrients deficiencies, diet-related chronic diseases, and obesity in all groups of the population in the region [5]. Due to this grave impact on chronic diseases, diet became a target of public health initiatives that aim at restoring the traditional diet of MENA countries in order to improve health conditions in their populations [68]. The epidemiology of diet-related diseases in the MENA region and background information on the diet-genetics-disease interaction, followed by nutrigenomic examples on diet-related diseases in the MENA region, will be discussed for the first time in this paper.

We review the numbers and trends for selected chronic metabolic diseases and micronutrient deficiencies in the different countries of the MENA where data are available (Figure 1). Given the lack of nationwide data, prevalence rates are commonly reported as estimations [9, 10]. Since 1982, the need for “direct evidence of a secular [increase]” in diseases has been established, prospecting an association with “acculturation” of traditional or rural populations [11]. Still, the numbers show alarming trends for cardiovascular diseases and metabolic disorders, namely, insulin resistance, adiposity, dyslipidemias, and atherosclerosis. Likewise, micronutrient deficiencies (MNDs) have been heavily studied recently due to their crucial contribution to the global burden of many chronic diseases.

The region is witnessing an “explosion” of Type 2 Diabetes Mellitus (T2DM) according to the International Diabetes Foundation (IDF) (Figure 2(a)) with five countries of the MENA ranking among the top ten diabetic worldwide [15]. Similarly, the IDF reports an increase in the incidence of Type 1 DM in children of the MENA over the past decade (Figure 2(b)). The World Health Statistics of the WHO show a sharp rise in the prevalence of obesity (Figure 3), which is the most powerful and easily reported risk marker and hence the sole epidemiological WHO indicator for cardiovascular and metabolic comorbidities. In one epidemiological study, cardiovascular mortality in the MENA has been estimated to triple from 1990 to 2020 (Figure 4). Table 1 summarizes rates of cardiovascular diseases and two major comorbid risk factors, hypertension and the metabolic syndrome, with wide variations across countries of the MENA.

Coronary artery disease (CAD)

IranAge-adjusted prevalence (%)12.7Nabipour et al. [73]
JordanPrevalence (%)5.9Nsour et al. [74]

Saudi Arabia,
 (rural)Prevalence (%)4.0Al-Nozha et al. [75]
 (urban)Prevalence (%)6.2
 (overall)Prevalence (%)5.5

TunisiaPrevalence (%), [men]12.5Ben Romdhane et al. [76]
Prevalence (%), [women]20.6

Cerebrovascular Accidents

BahrainAge-adjusted incidence (per 100,000)96.2Al-Jishi and Mohan [77]
IranAge-adjusted incidence (per 100,000)61.5Ahangar et al. [78]
KuwaitAge-adjusted incidence (per 100,000)92.2Abdul-Ghaffar et al. [79]
LibyaAge-adjusted incidence (per 100,000)114.2Radhakrishnan et al. [80]
PalestineAge-adjusted incidence (per 100,000)62.7Sweileh et al. [81]
QatarAge-adjusted incidence (per 100,000)123.7Hamad et al. [82]
Saudi ArabiaAge-adjusted incidence (per 100,000)38.5Al-Rajeh et al. [83]

Hypertension (HTN)

AlgeriaPrevalence (%), [Age > 25]36.2Yahia-Berrouiguet et al. [84]
BahrainPrevalence (%), [Age > 20]42.1Al-Zurba [85]

EgyptAge-adjusted prevalence (%)27.4Ibrahim et al. [86]
Prevalence (%), [Age > 25]26.3Galal [87]

IranPrevalence (%), [Age > 19]25.6Sarraf-Zadegan et al. [88]
Prevalence (%), [Age: 30–55]23.0Haghdoost et al. [89]
Prevalence (%), [Age > 55]49.5

IraqPrevalence (%), [Age > 20]19.3WHO: STEPwise, [90]
JordanPrevalence (%), [Age > 18]30.2Zindah et al. [91]
LebanonPrevalence (%), [Age: 18–65]31.2Sibai et al. [92]
MoroccoPrevalence (%), [Age > 20]33.6Tazi et al. [93]
OmanPrevalence (%), [Age > 20]21.5Hasab et al. [94]

Palestine (WB),
 (rural)Prevalence (%), [Age: 30–65]25.4Abdul-Rahim et al. [95]
 (urban)Prevalence (%), [Age: 30–65]21.5

QatarPrevalence (%), [Age: 25–65]32.1Bener et al. [96]
Saudi ArabiaPrevalence (%), [Age: 30–70]26.1Al-Nozha et al. [97]
SudanPrevalence (%), [Age: 25–64]23.6WHO: STEPwise, [90]
SyriaPrevalence (%), [Age: 18–65]40.6Maziak et al. [98]
TurkeyAge-adjusted prevalence (%)25.7Sonmez et al. [99]
UAEPrevalence (%), [Age > 20]20.8Baynouna et al. [100]
YemenPrevalence (%), [Age > 35]26.0Gunaid and Assabri [101]
Middle EastPrevalence (%), (overall)21.7Motlagh et al. [102]

Metabolic Syndrome

AlgeriaPrevalence (%), [Age > 20]17.4Mehio Sibai et al. [103]
IranPrevalence (%), [Age > 19]23.3Mehio Sibai et al. [103]
JordanPrevalence (%), [Age > 18]36.3Khader et al. [104]
KuwaitPrevalence (%), [Age > 20]24.8Al Rashdan and Al Nesef [105]
LebanonPrevalence (%), [Age: 18–65]25.4Mehio Sibai et al. [103]
Morocco, (rural)Prevalence (%), [women]16.3Rguibi and Belahsen [106]

 (overall)Prevalence (%), [Age > 20]21.0Al-Lawati et al. [107]
 (Nizwa)Age adjusted prevalence (%)8.0Al-Lawati et al. [107]

Palestine (WB)Prevalence (%), [Age: 30–65]17.0Abdul-Rahim et al. [95]

QatarPrevalence (%), [Age > 20]27.7Musallam et al. [108]
Age adjusted prevalence (%)26.5Bener et al. [109]

Saudi ArabiaAge adjusted prevalence (%)39.3Al-Nozha et al. [110]
TunisiaPrevalence (%), [Age > 20]16.3Bouguerra et al. [111]
UAEPrevalence (%)39.6Malik and Razig [112]

Nonadjusted rates from different studies are not valid for comparison but displayed to present the burden of the morbidities. HTN is defined as BP > 140/90 or use of antihypertensive medications. Metabolic Syndrome definition is based on Adult Treatment Panel III, except for Palestine and Tunisia where, respectively, WHO criteria and hypercholesterolemia (Total Cholesterol ≥5.2 mmol/l) instead of low HDL cholesterol were used. UAE: United Arab Emirates; WB: West Bank [103, 113116].

In the other category of diseases, deficiencies in vitamins and minerals affect particularly children and women of childbearing age. MNDs impair physical and mental development of children, exacerbate infections and chronic diseases, and impact morbidity and mortality. Most countries of the MENA have widespread MNDs, yet countries of the Gulf Cooperation Council, Iran, and Tunisia have moderate levels of MNDs [20]. Among MNDs, iron deficiency is the most prevalent nutritional problem in the MENA [21]. Its prevalence in the region varies from 17 to 70% among preschoolers, 14 to 42% among adolescents, and 11 to more than 40% among women of childbearing age. Severe iron deficiency is a direct cause of anemia. Nonnutritional genetic anemias are known to be relatively common in the region but will not be tackled because they are not affected by dietary factors. Nutritional deficiencies other than iron, such as folic acid, vitamin B12, and vitamin C, are also prevalent in some countries of the region but data are scarce [20]. The Middle Eastern and South Asian regions have the highest rates of Vitamin D Deficiency (VDD) worldwide [22]. The prevalence ranges of VDD in the MENA are 46–83% for adolescents and adults, and 50–62% among veiled women [5]. It reaches up to 70% in Iran [23] and 80% in Saudi Arabia [24]. Table 2 shows prevalence of VDD and iron deficiency in countries of the MENA where data are available.

Vitamin D deficiency (VDD)

IranPrevalence (%), [girls], [adolescent]Up to 70Moussavi et al. [143]

JordanPrevalence (%),
 [adult females]37.3Batieha et al. [144]
 [adult males]5.1

LebanonPrevalence (%),
 [girls]32El-Hajj Fuleihan et al. [145, 146]

Morocco (Rabat)Prevalence (%), [women]91Arabi et al. [147]
Saudi ArabiaPrevalence (%), [girls], [adolescent]Up to 80Siddiqui and Kamfar [148]
Tunisia (Ariana)Prevalence (%), [women], [Age: 20–60]47.6Arabi et al. [147]

Turkey (Ankara)Prevalence (%),
 [mothers]46Arabi et al. [147]

Iron deficiency

Arab Gulf countriesPrevalence (%),
 [children], [preschool age]20–67Musaiger [149]
 [children], [school age]12.6–50
 [pregnant women]22.7–54

BahrainPrevalence (%),
 [children], [Age: 6–59 months]48 Bagchi [150]
 [women], [Age: 15–49]37.3

EgyptPrevalence (%),
 [children], [Age: 6–59 months]25Bagchi [150]
 [women], [Age: 15–49]11

IranPrevalence (%),
 [children], [Age: 6–59 months]15–30Bagchi [150]
 [women], [Age: 15–49]33.4

JordanPrevalence (%),[children], [school age]20Bagchi [150]
Prevalence (%), [women], [Age: 15–49]28

LebanonPrevalence (%), [children], [Age: 6–59 months]23Bagchi [150]

MoroccoPrevalence (%),
 [children], [Age: 6–59 months]35Bagchi [150]
 [women], [Age: 15–49]30.1

OmanPrevalence (%),
 [children], [Age: 5–14]41Bagchi [150]
 [women], [Age: 15–49]40

PakistanPrevalence (%),
 [children], [Age: 6–59 months]60Bagchi [150]
 [women], [Age: 15–49]30

PalestinePrevalence (%),
 [children], [Age: 6–59 months]53Bagchi [150]
 [women], [Age: 15–49]36.2

Saudi ArabiaPrevalence (%), [children], [preschool age]17Bagchi [150]

SyriaPrevalence (%),
 [children], [Age: 6–59 months]23Bagchi [150]
 [women], [Age: 15–49]40.8

UAEPrevalence (%),
 [children], [Age: 6–59 months]34Bagchi [150]
 [pregnant women]14

YemenPrevalence (%), [children], [preschool age]70Bagchi [150]

Different limits of blood levels define VDD, ranging from insufficiency to severe deficiency, similar for Iron deficiency. UAE: United Arab Emirates [147, 150].

3. The Dietary Signature on the Genome

The effect of food on gene function is the focus of nutritional genomics, an emerging field of study that focuses on the molecular, cellular, and systemic levels of this effect [25, 26]. The abundance of calories, macro- and micronutrients, and bioactive food elements constitutes the nutritional environment that alters the genome, the epigenome, the posttranscriptional regulation, and the posttranslational modifications, leading to a variety of metabolic functional gene-products, as shown in Figure 5. The nutritional environment channels the function of gene-products into certain pathways, preferring certain biological activities over others and resulting in the final phenotypic outcome and health-disease status. Correspondingly, two disciplines of nutritional genomics are entertained: nutrigenomics and nutrigenetics. The former started as a focus on the effect of nutrients on gene expression, while the latter, yet a different field of study, emerged in search of approaches to alter the clinical manifestations of certain rare diseases, such as certain inborn errors of metabolism, via personalized diet. The link between them is the functional gene product. It is the end-point in nutrigenomics and the starting point in nutrigenetics. Other conventional terminologies relevant to the diet-genetics-disease relation will also be treated in the following section, prior to discussion of the dietary signature on the genome in the MENA.

(1) The genome sequence of DNA base pairs dictates the primary genetic profile and hence gene function. DNA sequence variants—gene variants and single nucleotide polymorphisms (SNPs)—designate an alteration of gene structure with or without functional changes that might or might not lead to a complex gene-function relationship depicted in different diseases [27]. The epigenome, an emerging concept in genetic research, is a set of nongenetic factors, such as diet, that change the expressed gene outcome without affecting the structure of the DNA per se.

(2) Nutrigenomics considers environmental factors of alimentary source that may disrupt the DNA sequence in peptide-coding and in promoter regions, affecting the gene product. Other environmental nutrigenomic factors include abundance of macro and micronutrient components of the diet, presence of other bioactive food elements, and caloric content. Under- or overnutrition in the maternal environment sets epigenetic programming mechanisms via energetic control of function and oxidation. Through regulation of many biological functions including mitochondrial activity, cellular stress, inflammation, and telomere shortening, the dietary signature starts when epigenetic mechanisms induce or limit the risk to disease [28]. Possible levels of expression of a certain gene lie in a range of disease susceptibility that is determined by epigenetic mechanisms. These mechanisms are dictated by the functional profile of the cell, which obeys its nutritional state and reflects the nutritional environment.

(3) Although sustainability of epigenetic programming along life span is not well understood [28], two temporally distinct profiles may be distinguished. First, the basal epigenome is determined early on in life. Depending on the basal expressivity of DNA, it behaves like a permanently edited version of the genome. Accordingly, increasing evidence of trans-generational inheritance of epigenetics was found in mice [29] through the effect of grandmaternal nutrition on grandchildren during gamete stage, throughout the mother’s fetal stage [30]. Second, later in life, similar mechanisms affect gene expressivity in response to temporary environmental factors, resulting in a short-lived epigenetic profile. These changes are mainly due to interference of nutrients and bioactive food components with transcription factor conformations [26]. This signature serves as a means for the organism to receive information about its nutritional environment in order for the cells to execute appropriate modifications on the profile of expressed genes [31]. The nutrigenomic signature is not well studied in humans yet; however obvious importance is due to its impact on gene expression, chronic diseases susceptibility, and health status of future generations [3133].

(4) Regulators of posttranscriptional modifications affect alternative RNA splicing which gives rise to different mature mRNA isoforms. Alternative splicing is as highly prevalent as in 35 to 59% of human genes [34]. Post-trancriptional regulators, such as microRNAs and their coacting and counteracting proteins, are part of the RNA and protein pools [35]. They are hence influenced by epigenetic and metabolic factors as well [26, 36].

(5) Proteomics is the study of the protein pool in the organism, as an integral part of the cellular function. On the other hand, the metabolome designates the structure, the localization, the post-translational modifications, and the functions of proteins and metabolites along with their interactions in the organism [37]. It defines the current metabolic state and active intracellular pathways in the organism (Figure 5). The functional gene products comprise all the potentially functional molecules and pathways, whether currently active or not, that result from a certain genome-epigenome combination, leading to a certain range of possible phenotypic outcomes, rather than a clearly defined health status.

(6) Nutrigenetics is a quite different approach that emerged when dietary interventions were able to successfully alter the course of certain diseases. The basic principle considers how the same dietary environment can result in different phenotypic outcomes of health or disease in metabolizers with different functional gene-products or programmed phenotypes [38]. The concept is similar to how individuals possess different phenotypes as drug-metabolizers. The study of genetic variations affecting nutrient metabolism, from digestion to detoxification, can decipher ambiguities in the diet-disease relationship [38]. However, the challenge lies in the ability of researchers to describe the processes through which the dietary environment imposes itself to precipitate metabolic disorders.

(7) Finally, hypotheses of Thrifty Profile, namely thrifty genes and thrifty phenotypes, offer explanations for etiology, predisposition, and rising prevalence of DM and obesity. Early life dietary habits foretell the basal appetite control and cellular nutritional needs through psychological and molecular habituations [28]. Thrifty genes that enable survival during periods of food shortages may have been conserved over generations under the selection pressure of under-nutrition [39]. Thrifty phenotypes may be due to early nutritional challenges that enhance nutrients-saving mechanisms in the growing individual, leading to excessive storage later on and increased risk of metabolic disorders [40]. Both models have not gathered enough evidence apiece; however combined they provide a fertile base for further nutritional genomic research.

An example of a phenotype that has evolved accordingly is taste preferences and ability to digest, absorb, and appropriately respond to nutrients [41]. Genes for taste receptors, among other proteins that handle the metabolism of different nutrients, have been extensively studied. In an extensive review by Garcia-Bailo et al., an important aspect of the dietary signature is addressed: the genetic variations that affect dietary habits and food choices, with an emphasis on their effects on the nutritional environment and the health outcome [41].

Given the rise in multifactorial diseases, nutrigenetics started to involve public health research, hinting at personalized dietary recommendations for prevention of civilization diseases many years before clinical manifestations arise [31]. Adequacy of the general dietary recommendations to the ancient nature of our genes is becoming increasingly dubious. The human genome, as we know it, was sculpted throughout 2 million years of evolution under the diets of our hunters-gatherers ancestors [42]. Later on, the available food choices changed since the introduction of agriculture, but too rapidly for the ancestral stone-age genome to keep up with. This fast nutritional transition revealed evolutionary origins of obesity and diabetes among other civilization epidemics [43]. The experiment-based advancement of dietary recommendations during the past 25 years showed a convergence towards what looks more like a Paleolithic hunter-gatherer diet [44]. Despite low compliance to recommended diets and increasing industrialization of actual dietary habits, personalized and ancestral dietary recommendations still seem promising.

4. Nutritional Genomics in the MENA

Diet, genetics, and disease are linked in many ways as could be shown in Figure 5. The MENA is a region that has been witnessing simultaneously a dietary change and a worsening prevalence of chronic diseases. Because of this, nutritional genomics research in such a region can improve our understanding of this rapid change in disease prevalence and shed light on the genomic effects of this dietary transition in the region. Nutritional genomics research in the MENA is minimal. To our knowledge, this is the first review on the topic in the region. We aim to collate studies in MENA countries that discuss any aspect of the dietary signature that we discussed in Figure 5. We approach that using examples of common diseases with rising prevalence in the MENA. The paper discusses two categories of diseases: (1) civilization disorders of metabolism (cardiovascular diseases and metabolic risk factors), and (2) micronutrient deficiencies (MNDs).

We also look at other populations where nutritional genomics research in these disease categories was done and discuss how it applies to our region with recommendations for future research on MENA populations.

Populations of the MENA belong to a unique genetic pool because of the mixture of ethnicities with horizontal mixing of populations throughout history, the high rate of consanguineous marriages within subpopulations, and the geography of the states making up the region (Figure 1). Nevertheless, wide prospective population studies on the effects of polymorphisms on such disorders of metabolism in the MENA are still lacking [25]. Based on literature reports on other populations, a large set of genes and DNA sequence variants are potentially culpable of the rise of metabolic disorders under the effect of industrialized diets. In this part of the paper, we present numerous polymorphisms that predispose to metabolic disorders including T2DM, obesity, dyslipidemias, atherosclerosis, cardiovascular events, and hypertension. The civilization disorders have common pathophysiologies and risk factors of metabolism and, since interrelated and comorbid, will accordingly be treated as one major health outcome in the following discussion about genetic entities common to the different disorders, under the effect of diet.

The Brain-Derived Neurotrophic Factor (BDNF) is important for energy balance in mice and for regulation of stress response in humans (OMIM 113505). Polymorphisms in this gene are associated with obesity and all subtypes of psychological eating disorders in Europeans (NCBI 627). Recently, three-way association was identified between hoarding behavior of obsessive-compulsive disorder, obesity, and the Val/Val genotype of BDNF in the Valine (Val) to Methionine (Met) amino acid change at position 66 (Val66Met) in Caucasians [45]. The suggested evolutionary mechanism for this complex relationship between gene, psychopathology, and body weight is the conservation of a thrifty gene, once an old survival strategy.

Control of fetal appetite was recently shown to be a function of the Fat Mass- and Obesity-Associated (FTO) gene expression [28] which codes a nuclear oxygenase that affects tissue lipid metabolism [46] (NCBI 79068) and depends on energy balance during development [28]. A strong relation links FTO SNPs to higher risk of obesity and T2DM in many international studies (OMIM 610966) [47, 48].

Transcription Factor 7-Like 2 (TCF7L2) gene codes a transcription factor involved in blood glucose homeostasis. The rs7903146 variant association to T2DM varies greatly over ethnicities (OMIM 602228). However in Palestinians, this SNP (114758349C > T) increases the risk for T2DM, and homozygotes are affected at younger age [49].

Calpain 10 (CAPN10), which codes a calcium-dependent cysteine protease, is being increasingly studied for its role in T2DM (NCBI 11132). SNP-44 of CAPN10 has significant association with T2DM and total cholesterol in Gaza [50], while only UCSNP-19 SNP and haplotype-111 are proven to be high risks for T2DM in Tunisia [51].

The association of T2DM with polymorphisms of the Angiotensin Converting Enzyme (ACE) and the Methylene Tetrahydrofolate Reductase (MTHFR) is not well proven [52]. However data in Tunisians suggest synergistic action of the ACE Insertion/Deletion (I/D) dimorphism with the MTHFR C677T SNP on risk of T2DM [52]. Fairly common, ACE D and MTHFR 677T alleles are, respectively, present in around 77 and 27% of Moroccans [53]. Nevertheless, ACE DD genotype in Tunisians is associated with higher ACE activity and might become a useful clinical marker for CAD risk assessment of acute myocardial infarction [52, 54]. In Lebanon, ACE D allele and age, combined, are associated with higher risk for hypertension [54]. Also, Lebanese with MTHFR C677T turned out to be more susceptible to diabetic nephropathy than Bahrainis with the same SNP [55]. The SNP cannot constitute an independent risk factor in Arabs [56]. Its effect is presumably due to high homocysteine levels and hence must be evaluated depending on dietary and ethnic backgrounds [55].

In genes encoding the G protein-coupled Beta-2- and 3-Adrenergic Receptors (ADRB2, ADRB3), evolutionary selection of specific alleles exists in Africans, Asians, and Europeans. ADRB2 Glu27 and Gln27 are, respectively, factors of exercise-dependent obesity risk and metabolic syndrome susceptibility (OMIM 109690). Glu/Glu and Glu/Gln can independently predict severe Coronary Artery Disease (CAD) in Saudi Arabs [57]. However ADRB3 Trp64Arg SNP is a CAD predictor only in presence of other risk factors in Arabs, but not an independent one [57]. ADRB3 is mainly located in adipose tissues causing easier weight gain and earlier T2DM onset in Trp64Arg individuals in several populations [58] (NCBI 155) (OMIM 109691).

Peroxisome Proliferator-Activated Receptor Gamma (PPARG) genes encode nuclear receptors and regulators of adipocyte differentiation and possibly lipid metabolism and insulin sensitivity (OMIM 601487). Pro12Ala isoform of PPARG2 seems to activate transcription less effectively and carry less morbidity. Carriers of a Pro12Ala polymorphism may have a weaker BMI correlation to amount of dietary fat when compared to Pro homozygotes [59], while response to quality of dietary fat is greater in terms of BMI, lipid profile, and fasting insulin levels [60, 61]. However these associations were not found for many of the studied populations (OMIM 601487).

Apolipoproteins (APOs) are involved in lipid metabolism. APOE polymorphisms have been heavily studied. In the APOE G219T SNP, TT individuals have prolonged postprandial lipemia [62]. Apo E has three major isoforms, E2, E3, or E4. APOE E4 individuals may be protected effectively by lower dietary fat intake [63] while non-E4 individuals have minimal to no benefit from dietary intervention on lipid profile [64]. In Iranians, E2 allele was associated with lower total cholesterol levels [65]. However, despite correlation between APOE2 and LDL subfraction profiles in healthy Arabs, no similar association was found in Arabs with CAD [66]. APOE E2, E3, and E4 carriers constitute approximately 11, 79, and 10% of Moroccans, respectively [53].

Moreover, mutations in Lipoprotein Lipase (LPL), which is crucial for receptor-mediated lipoprotein uptake, drastically affect lipoprotein metabolism disorders (NCBI 4023). In Saudi Arab population however, lack of association between LPL polymorphisms and CAD was noticed [56]. Strong evidence exists for Hepatic Lipase (LIPC) C514T homozygotes. They have more atherogenic lipid profile in response to dietary fat in addition to impaired adaptation to higher animal fat with higher cardiovascular diseases risk [67, 68].

Finally, the Paraoxonase (PON1) gene encodes for an anti-atherosclerotic esterase which capacitates high-density lipoproteins to prevent lipoprotein oxidation. Gln192Arg and Leu55Met are two common polymorphisms of PON1 that modulate PON1 activity in the serum, which predicts the architecture of apolipoprotein, lipoprotein, and lipid levels [69]. In the late 1990s, PON1 status, including genotype and serum activity levels, has been proven to predict cardiovascular risk much better than genotype alone [70]. However, in Turkish subjects, there was no consistent association between the polymorphisms and the lipid levels [71]. An individual’s polymorphism might be suggestive of a high risk while his dietary signature is making the actual PON1 activity favorable, that is, low risk. This interaction between diet and genes can hinder the significance of genetic screening, and enhance the relevance of proteomics and metabolomics. The lesson learned from the PON1 role in cardiovascular disease is of utmost relevance. Functional genomic analysis is required for adequate risk assessment; an individual may be screened for all known polymorphisms of PON1, but still not be assigned a risk category for cardiovascular disease [72].

Discrepancies between genotype and function impose limitations on genetic screening. Similarly for most of the polymorphisms presented previously, the degree to which genetic screening can be helpful in decision-making is controversial. More activity correlation studies are needed to examine the “penetrance” of polymorphisms. Also, insufficient nutrigenomic and proteomic evidence may be misleading [117]. Hence, further multidisciplinary studies, with coordination between laboratories, will be needed to decide which gene/polymorphism would be worth screening in a particular population.

Further multidisciplinary nutritional genomics research is needed for more specific targeted individualized advising and therapy. However, given the current lack of adequate understanding of the genetic etiologies of civilization diseases and wide-scale regional genetic screening studies, reversal of dietary changes is rendered the simplest available measure to control the metabolic epidemic of civilization diseases in the MENA.

6. Micronutrient Deficiencies (MNDs) in the MENA Region

Micronutrients (vitamins and minerals) are required throughout life, in minute amounts in the human body, to function as cofactors of enzymes or as structural components of proteins, or to maintain genome stability, among other physiological roles [118]. Both their excess and deficiency may cause DNA damage, alter growth and development, contribute to a wide array of chronic diseases, and jeopardize health [118]. MNDs are highly prevalent in MENA countries as was established earlier. Deficiencies in iodine, iron, and vitamin A are very important MNDs in terms of prevalence and potential threat to public health worldwide; however relevant gene-diet interaction has not been sufficiently studied in the MENA. This section will thus be restricted to the following MNDs of particular interest in diet-genetics-disease interaction: vitamin D, calcium, iron, folate, and vitamins C, E, B6, and B12.

6.1. Vitamin D Deficiency (VDD)

Vitamin D is a fat-soluble vitamin, with two forms, one present in a narrow range of foods (D2) and another formed under the skin when exposed to the ultraviolet B (UVB) light fraction of sunlight (D3); both are activated by the liver and kidneys [119] (Figure 6). Prolonged VDD can result in rickets in young children and osteoporosis and fractures in adults [120]. Recently, low vitamin D levels have been associated with increased risk of hypertension, cardiovascular diseases [121], cancer [122], diabetes [123], musculoskeletal and immunity disorders, and infectious diseases [124].

Despite the sunny climate, the MENA has a highly prevalent VDD across all age groups, with the highest rate of rickets worldwide [22]. The main reasons are limited sun exposure and low dietary vitamin D intake, along with frequent pregnancies, short breastfeeding periods [125], skin pigmentation [126], body mass index [127], religious practices [128], and educational levels [129].

In addition to nutritional and social factors of VDD, genetic factors also play an important role and are depicted on the metabolic pathway of vitamin D shown in Figure 6. Genetic variations predisposing to VDD are related to Vitamin D Receptor (VDR) polymorphisms at intron 8 (BsmI) and exon 2 (FokI) [130]. The Fok1 polymorphism (C>T) in the translation initiation site creates an upstream initiation codon and a three amino acids longer molecule in the f allele compared to the F allele [131] which gives a more transcriptionally active VDR [132] leading to the tolerance to low vitamin D levels observed in Egyptian FF homozygotes [130]. This suggests possible evolutionary adaption to dietary intake or lifestyle changes. Only FF homozygote children have increased calcium absorption and bone mineral density [131]. Conversely, the decreased calcium absorption linked to the f allele was correlated with an increase in colon cancer risk only when calcium dietary intake is low [133]. FF genotype seems hence more advantageous than ff genotype. Paradoxically, FF (shorter VDR) was correlated with rickets unlike ff (longer VDR) in Turks and Egyptians. Thus, further studies are needed to understand the complex genetics and risks of rickets. VDR B allele also predisposes to VDD since Egyptian B homozygotes had severe rickets [130]. In other studies in the Middle East, high vitamin D doses were needed to treat patients with rickets [134]. Thus, the unexpected high prevalence of VDD in the MENA could be linked to VDR polymorphisms.

Moreover, a G>A polymorphism at position −3731 of the cdx-2 (Caudal-Type Homeobox Transcription Factor) binding element on the VDR gene promoter is another genetic variant of VDR that affects calcium absorption. The Cdx2 promoter A allele (cdx-A) binds cdx2 more strongly and has a greater transcriptional activity compared to the cdx-G allele. Thus, the A allele may increase intestinal VDR expression, subsequently enhancing calcium intestinal absorption and increasing bone mineral density. The differential expression of VDR shows how genetic differences influence the body response to nutrients [135].

Bioactive food components may exert an effect on gene expression and enzyme activity, subsequently decreasing disease risk. For example, 4′,5,7-Trihydroxyisoflavone (genistein), a soy component, is a genome-protective nutrient. It inhibits the activity of CYP24A1 (Figure 6) and thus 1,25(OH)2D degradation, increasing VDR stability and the half-life and biological effects of vitamin D [136]. Folate can also inhibit this activity by increasing methylation of the promoter of CYP24A1. Also, addition of vitamin D and calcium to the western diet significantly decreases the incidence of colon cancer [133].

6.2. Iron Deficiency

Iron (Fe) is an essential mineral needed in small amounts mainly for the production of hemoglobin and utilization of oxygen among other vital functions. Iron deficiency is a common MND mostly caused by low intake of iron, blood loss, and parasitic infections [137]. Iron absorption is enhanced by vitamin C, low pH, and heme iron and hindered by bioactive vegetables components (polyphones, tannins, phytates) and calcium [138].

Genetic factors that contribute to iron deficiency, in addition to the dietary intake, are underscored by the ability of many individuals to maintain normal iron levels despite low iron dietary intake. Nutritional iron deficiency and genetic iron deficiency have been experimentally distinguished in mice. Hephaestin (Heph) is a multicopper oxidase that allows iron basolateral surface export. Sex-linked anemia (Sla) mice bearing a deletion in Heph gene compared to control mice showed different responses to diet; Sla mice had duodenal iron accumulation and low plasma iron [139]. Additionally, mutations in the genes of human hemochromatosis protein (HFE) and its interacting protein beta-2 microglobulin (B2M), which play an important role in iron metabolism, cause murine iron deficiency [140].

6.3. Folate Deficiency

Folic acid is a water soluble B vitamin of exclusive dietary origin. It provides the one-carbon metabolism with its main coenzyme form, tetrahydrofolate (THF). A key enzyme herein, methylenetetrahydrofolate reductase (MTHFR), catalyzes vitamin B12-dependent conversion of homocysteine to methionine, a precursor of S-adenosylmethionine (SAM), a methyl donor to DNA [141]. Thus, folate deficiency results in hyperhomocysteinemia (HHC), a risk factor for CAD [142].

MTHFR C677T is prevalent in 4% of Pakistanis [32], 2% of Yemenite Jews, 10% of Muslim Arab Israelis, and 11% of Lebanese [151]. It leads to a thermolabile MTHFR, which precipitates HHC in low folate states. This gene-environment combination is a risk factor for cardiovascular diseases [152], neural tube defects, and other chronic diseases [153].

C677T is a genetic variation that affects individual dietary requirements because it makes prevention of folate-related diseases that require higher folate intake. Korean C homozygotes develop HHC only with low folate levels, while T homozygotes have HHC even with normal folate levels [154]. Surprisingly however, the hyperhomocysteinemia, low folate levels, and increased cardiovascular risk observed in Indian Asians compared to European whites were not attributed to the MTHFR 677T variant [155]. Studies specific to the MENA are therefore needed because of possible variations from other regions.

The example of MTHFR and folate also underscores the genome-epigenome interplay. The TT genotype alters DNA methylation and gene expression in peripheral blood mononuclear cells only in folate deficient patients [156]. Paradoxically, the same polymorphism is inversely associated with and hence has a protective role against colorectal cancer (CRC). CRC risk decreases with adequate methionine intake, which leads to an increased formation of SAM and a negative feedback inhibition of MTHFR activity. However, the protective roles of MTHFR mutation and methionine dietary intake require an adequate dietary folate intake [157]. These findings suggest that inadequate folate intake puts carriers of particular genetic variants at higher risk of cancer. Thus personalized dietary interventions might be beneficial in reducing cancer risks.

Serum vitamin B12 deficiency is highly prevalent in Iran [158]. Thus, low folate and vitamin B12 levels can be inversely linked to the hyperhomocysteinemia observed in this population. Importantly, high prevalence of CAD was observed in a Turkish population with low plasma folate despite low plasma cholesterol concentrations [159]. It remains to determine the link between hyperhomocysteinemia, low folate intake, CAD risk, and MTHFR variants, to explain this prevalence in Turkey and possibly in other countries of the MENA region. This would add folate supplementation as a possible treatment for hyperhomocysteinemia. Other studies have also reported the possible contribution of the level of pyridoxal phosphate (PLP or vitamin B6) to hyperhomocysteinemia and vascular disease; low PLP levels were observed in individuals with the homozygote TT genotype compared to healthy individuals from some countries of the MENA [160, 161]. These data corroborate the various dietary signatures on the specific genetic profile and show that other mechanisms, enzymes, and vitamins should be examined as well.

6.4. Vitamin B12 Deficiency

Like folate deficiency, vitamin B12 (cobalamin) deficiency can affect establishment of the disease depending on the genetic background. A common genetic variant is detected in Methionine Synthase Reductase (MTRR), an important enzyme for maintaining Methionine Synthase in its active state. The polymorphism is an A66G substitution resulting in an Ile22Met residue. The homozygous genotype was associated with an increased risk of neural tube defects (NTDs) when combined with low vitamin B12 levels. Vitamin B12 deficiency is highly prevalent among Iranian women of childbearing age [158]. However polymorphisms in both MTHFR and MTRR increase NTDs risk [162].

6.5. Vitamins C and E Deficiencies

As antioxidants, vitamins C and E have an important function in the diet-gene interaction. Glutathione S-transferases (GSTs) transfer glutathione to different substrates. A common deletion of GSTM1 gene, a deletion polymorphism in GSTT1, and an A313G polymorphism of GSTP1 result, respectively, in a nonfunctional genotype, loss of enzyme activity, and altered activity of the GST isoforms. The GST enzymes were found protective against serum ascorbic acid deficiency when vitamin C consumption is low, since GST null genotypes with low vitamin C intake had an increased serum ascorbic acid deficiency risk [163]. The Hp1 and Hp2 polymorphisms in the hemoglobin-binding protein haptoglobin (Hp) were also studied in vitamin C deficiency. Unlike Hp1 carriers, Hp2 homozygotes had lowest serum vitamin C concentrations when dietary vitamin C intake is insufficient. Thus, Hp1 has a greater antioxidant capacity preventing hemoglobin-iron-related vitamin C oxidation and depletion [164].

A protective role for vitamin E against atherosclerosis, cancer, and neurodegenerative diseases has also been reported. Polymorphisms in the proteins involved in vitamin E metabolism lead to differential vitamin E uptake and response among individuals, and subsequently different disease risk [165]. Dietary vitamin E intake also influences the body mass index (BMI) and risk of obesity via modifying genetic variants of SIRT1 (sirtuin protein family of nicotinamide-adenine-dinucleotide- (NAD+)-dependent histone deacetylases) [166].

Well-studied gene-diet interactions are also critical in the pathophysiology of cancer. Given the evidence that VDR polymorphisms, MTHFR genotype, and DNA methylation in a low calcium or folate intake are associated with an increased cancer risk, the dietary signature greatly influences carcinogenesis. Significant dietary factors include antioxidants such as vitamin C, carotenoids, lycopene, tocopherols (vitamin E), and many other micronutrients present in fruits and vegetables.

Being one of the leading causes of death worldwide as well as in the MENA, cancer has been extensively studied, and the diet-genetics-cancer interaction is currently being thoroughly investigated for each and every one of the involved micronutrients. So, the effect of the diet-genetics interaction on carcinogenesis will not be dwelled upon in this paper.

The aforementioned studies collectively depict the interaction between diet, genetic variability, and disease. Genetic variants might affect gene expression patterns and epigenetic events resulting in differential body responses to diet. However, a small individualized nutritional intervention that is well studied to provide the needed concentrations of micronutrients can influence genetic variants to decrease disease risk. Thus, nutrigenetics is a tool for choosing the appropriate diet according to the individual’s genetic makeup.

7. A Call for Nutritional Genomics Research in the MENA

All previous data support the crosstalk between diet and genome. Differential responses to dietary components among individuals are determined by genetic factors. The deleterious effects of some genotypes can be circumvented by an increased intake of particular nutrients to overcome the genetic susceptibility, which opens the horizon for personalized diet. In turn, nutrients might affect genome, gene expression, and phenotype. Although hard and complex, it is worthwhile to identify the genes that predispose individuals to chronic diseases and the nutrients that regulate their expressions to modify personal risks and to prevent, mitigate, or treat diseases. Studying on an individual basis the interactions between diet and genetics could help select appropriate diet to optimize health status. Indeed, the picture becomes more complicated when lifestyle, behavioral, and other environmental factors interfere with the diet-genetics interaction.

Of note is the unique ethnic combination of the region’s native populations that make studies from other regions inapplicable to the MENA. In spite of the multiethnic origins, high rates of consanguinity in the subpopulations render the genetic pool paradoxically limited and significantly increase not only the risk of congenital abnormalities but also the susceptibility of the population to chronic diseases and genetic disorders [167]. Screening for the common polymorphisms in the MENA can give insights on their prevalence in the region or can help discover polymorphisms indigenous for the region. Such action could help alleviate the burden of chronic diseases in the MENA simply by suggesting adequate adjustments of dietary factors to hide a genetic polymorphism or to prevent DNA damage.

In some of the examples provided previously, success can be achieved, but in others, researchers ought to be more cautious. Selecting which polymorphisms are to be screened for, at the population level in the MENA, should be made after careful understanding of the effects of these variants on diet and disease. This is crucial to avoid misleading results and unnecessary costs. Unfortunately, functional studies are limited, but wide-scale screening and associations from other regions in the world could guide the decision-making process regarding screening in the MENA. At the same time, more effort and money should be invested in molecular and cellular research in nutritional genomics in order to better understand the function of the dietary signature and to more confidently guide population screening and personalized diet.

8. Conclusions

(i)MENA countries are witnessing a radical change in dietary patterns from a traditional diet to a less healthy industrialized diet.(ii)Rising prevalence for civilization diseases of metabolism and micronutrient deficiencies in the MENA parallels the change in dietary habits and is mostly caused by it.(iii)Nutrigenomic factors and the dietary signature on the genome play a role in the diet-disease interactions.(iv)Genetic sequence variations, epigenetic profiles, and posttranscriptional and posttranslational modifications are some of the mechanisms that define the diet-genetics-disease relationship.(v)A large set of gene polymorphisms have been correlated with civilization diseases of metabolism, only a little of which have been studied in MENA countries.(vi)There are different mechanisms through which diet-genetics interaction affects micronutrient pathways and contributes to disease, including vitamin D and calcium, iron, folate, and vitamins C and E.(vii)Given the drastic dietary changes in the region over a short period of time, diet is the most obvious public health intervention, yet system biology and genomics research should not be underestimated.(viii)Wide-scale screening for certain gene polymorphisms in the MENA might allow for efficient intervention with personalized diet.(ix)More nutrigenomics research is needed to look at function and mechanisms of the diet-genetics-disease interaction.


MENA:Middle East and North Africa
WHO:World Health Organization
OMIM:Online Mendelian Inheritance in Man
NCBI:National Center for Biotechnology Information
SNP:Single Nucleotide Polymorphism
MNDs:Micronutrient Deficiencies.

Conflict of Interests

The authors declare that they have no conflict of interests.

Authors’ Contribution

A. C. Fahed and G. M. Nemer designed the narrative review and the different sections of the manuscript, supervised the work, and compiled the final draft. A. M. El-Hage-Sleiman and T. I. Farhat performed the literature search, designed the figures, and wrote equally different sections of the manuscript. A. K. M. El-Hage-Sleiman and T. I. Farhat contributed equally to this paper. All authors read and approved the final manuscript.

Authors’ Information

A. C. Fahed is a postdoctoral research fellow at the Harvard Medical School Department of Genetics. G. M. Nemer is an Associate Professor of Biochemistry and Molecular Genetics at the American University of Beirut (AUB). A. M. El-Hage-Sleiman is a medical student and T. I. Farhat is a graduate student in Biochemistry and Molecular Genetics, both at the AUB.


The authors would like to thank all the Nemer Lab team members for their support during the preparation of this work. They would also like to thank Dr. Amy Zenger from the Writing Center at the American University of Beirut for editing the manuscript.

Supplementary Materials

Supplementary Material: shows references for tables and figures.

  1. Supplementary Material


  1. D. Grigg, “Food consumption in the Mediterranean region,” Tijdschrift voor Economische en Sociale Geografie, vol. 90, no. 4, pp. 391–409, 1999. View at: Google Scholar
  2. A. O. Musaiger, “Diet and prevention of coronary heart disease in the Arab Middle East countries,” Medical Principles and Practice, vol. 11, supplement 2, pp. 9–16, 2002. View at: Publisher Site | Google Scholar
  3. A. Belal, “Nutrition-related chronic diseases Epidemic in UAE: can we stand to STOP it?” Sudanese Journal of Public Health, vol. 4, pp. 383–392, 2009. View at: Google Scholar
  4. A. Alwan, “Noncommunicable diseases: a major challenge to public health in the Region,” Eastern Mediterranean Health Journal, vol. 3, pp. 6–16, 1997. View at: Google Scholar
  5. K. Bagchi, “Iron deficiency anaemia—an old enemy,” Eastern Mediterranean Health Journal, vol. 10, no. 6, pp. 754–760, 2004. View at: Google Scholar
  6. D. C. Klonoff, “The beneficial effects of a Paleolithic diet on type 2 diabetes and other risk factors for cardiovascular disease,” Journal of Diabetes Science and Technology, vol. 3, no. 6, pp. 1229–1232, 2009. View at: Google Scholar
  7. A. Trichopoulou, T. Costacou, C. Bamia, and D. Trichopoulos, “Adherence to a Mediterranean diet and survival in a Greek population,” The New England Journal of Medicine, vol. 348, no. 26, pp. 2599–2608, 2003. View at: Publisher Site | Google Scholar
  8. S. Russeau and M. Batal, The Healthy Kitchen, Recipes from Rural Lebanon, Ibsar, Nature Conservation Center for Sustainable Futures American University of Beirut, 2009.
  9. P. Mirmiran, R. Sherafat-Kazemzadeh, S. Jalali-Farahani, and F. Azizi, “Childhood obesity in the Middle East: a review,” Eastern Mediterranean Health Journal, vol. 16, no. 9, pp. 1009–1017, 2010. View at: Google Scholar
  10. S. Yusuf, S. Reddy, S. Ôunpuu, and S. Anand, “Global burden of cardiovascular diseases part II: variations in cardiovascular disease by specific ethnic groups and geographic regions and prevention strategies,” Circulation, vol. 104, no. 23, pp. 2855–2864, 2001. View at: Google Scholar
  11. P. Zimmet, D. Canteloube, and B. Genelle, “The prevalence of diabetes mellitus and impaired glucose tolerance in Melanesians and part-Polynesians in rural New Caledonia and Ouvea (Loyalty Islands),” Diabetologia, vol. 23, no. 5, pp. 393–398, 1982. View at: Google Scholar
  12. International Diabetes Federation, IDF Diabetes Atlas, 1st edition, 2000,
  13. International Diabetes Federation, IDF Diabetes Atlas, 2nd edition, 2003,
  14. International Diabetes Federation, IDF Diabetes Atlas, 3rd edition, 2007,
  15. International Diabetes Federation, IDF Diabetes Atlas, 4th edition, 2010,
  16. S. Wild, G. Roglic, A. Green, R. Sicree, and H. King, “Global prevalence of diabetes: estimates for the year 2000 and projections for 2030,” Diabetes Care, vol. 27, no. 5, pp. 1047–1053, 2004. View at: Publisher Site | Google Scholar
  17. WHS, World Health Statistics Annual, 2005,
  18. WHS, World Health Statistics Annual, 2011,
  19. S. Yusuf, S. Reddy, S. Ôunpuu, and S. Anand, “Global burden of cardiovascular diseases. Part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization,” Circulation, vol. 104, no. 22, pp. 2746–2753, 2001. View at: Google Scholar
  20. WHO, Draft Nutrition Strategy and Plan of Action for Countries of the Eastern Mediterranean Region 2010–2019, 2009.
  21. O. M. Galal, “Micronutrient deficiency conditions in the middle east region: an overview,” Public Health Reviews, vol. 28, no. 1–4, pp. 1–12, 2000. View at: Google Scholar
  22. A. Mithal, D. A. Wahl, J. P. Bonjour et al., “Global vitamin D status and determinants of hypovitaminosis D,” Osteoporosis International, vol. 20, no. 11, pp. 1807–1820, 2009. View at: Publisher Site | Google Scholar
  23. M. Moussavi, R. Heidarpour, A. Aminorroaya, Z. Pournaghshband, and M. Amini, “Prevalence of vitamin D deficiency in Isfahani high school students in 2004,” Hormone Research, vol. 64, no. 3, pp. 144–148, 2005. View at: Publisher Site | Google Scholar
  24. A. M. Siddiqui and H. Z. Kamfar, “Prevalence of vitamin D deficiency rickets in adolescent school girls in Western region, Saudi Arabia,” Saudi Medical Journal, vol. 28, no. 3, pp. 441–444, 2007. View at: Google Scholar
  25. J. M. Ordovas and V. Mooser, “Nutrigenomics and nutrigenetics,” Current Opinion in Lipidology, vol. 15, no. 2, pp. 101–108, 2004. View at: Publisher Site | Google Scholar
  26. G. P. A. Kauwell, “Emerging concepts in nutrigenomics: a preview of what is to come,” Nutrition in Clinical Practice, vol. 20, no. 1, pp. 75–87, 2005. View at: Google Scholar
  27. R. G. Gosden and A. P. Feinberg, “Genetics and epigenetics—nature's pen-and-pencil set,” The New England Journal of Medicine, vol. 356, no. 7, pp. 731–733, 2007. View at: Publisher Site | Google Scholar
  28. S. Sebert, D. Sharkey, H. Budge, and M. E. Symonds, “The early programming of metabolic health: is epigenetic setting the missing link?” American Journal of Clinical Nutrition, vol. 94, no. 6, pp. 1953S–1958S, 2011. View at: Publisher Site | Google Scholar
  29. R. A. Waterland and R. L. Jirtle, “Early nutrition, epigenetic changes at transposons and imprinted genes, and enhanced susceptibility to adult chronic diseases,” Nutrition, vol. 20, no. 1, pp. 63–68, 2004. View at: Publisher Site | Google Scholar
  30. S. M. Singh, B. Murphy, and R. L. O'Reilly, “Involvement of gene-diet/drug interaction in DNA methylation and its contribution to complex diseases: from cancer to schizophrenia,” Clinical Genetics, vol. 64, no. 6, pp. 451–460, 2003. View at: Publisher Site | Google Scholar
  31. R. Debusk, “The role of nutritional genomics in developing an optimal diet for humans,” Nutrition in Clinical Practice, vol. 25, no. 6, pp. 627–633, 2010. View at: Publisher Site | Google Scholar
  32. P. J. Stover, “Influence of human genetic variation on nutritional requirements,” American Journal of Clinical Nutrition, vol. 83, no. 2, 2006. View at: Google Scholar
  33. R. L. Jirtle and M. K. Skinner, “Environmental epigenomics and disease susceptibility,” Nature Reviews Genetics, vol. 8, no. 4, pp. 253–262, 2007. View at: Publisher Site | Google Scholar
  34. B. Modrek and C. Lee, “A genomic view of alternative splicing,” Nature Genetics, vol. 30, no. 1, pp. 13–19, 2002. View at: Publisher Site | Google Scholar
  35. W. Filipowicz, S. N. Bhattacharyya, and N. Sonenberg, “Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight?” Nature Reviews Genetics, vol. 9, no. 2, pp. 102–114, 2008. View at: Publisher Site | Google Scholar
  36. C. D. Davis and J. Milner, “Frontiers in nutrigenomics, proteomics, metabolomics and cancer prevention,” Mutation Research, vol. 551, no. 1-2, pp. 51–64, 2004. View at: Publisher Site | Google Scholar
  37. A. Pardanani, E. D. Wieben, T. C. Spelsberg, and A. Tefferi, “Primer on medical genomics part IV: expression proteomics,” Mayo Clinic Proceedings, vol. 77, no. 11, pp. 1185–1196, 2002. View at: Google Scholar
  38. A. El-Sohemy, “Nutrigenetics,” Forum of Nutrition, vol. 60, pp. 25–30, 2007. View at: Publisher Site | Google Scholar
  39. J. V. Neel, “Diabetes mellitus: a "thrifty" genotype rendered detrimental by "progress"?” American Journal of Human Genetics, vol. 14, pp. 353–362, 1962. View at: Google Scholar
  40. R. S. Lindsay and P. H. Bennett, “Type 2 diabetes, the thrifty phenotype—an overview,” British Medical Bulletin, vol. 60, pp. 21–32, 2001. View at: Publisher Site | Google Scholar
  41. B. Garcia-Bailo, C. Toguri, K. M. Eny, and A. El-Sohemy, “Genetic variation in taste and its influence on food selection,” OMICS, vol. 13, no. 1, pp. 69–80, 2009. View at: Publisher Site | Google Scholar
  42. S. B. Eaton and S. B. Eaton, “Paleolithic vs. modern diets—selected pathophysiological implications,” European Journal of Nutrition, vol. 39, no. 2, pp. 67–70, 2000. View at: Google Scholar
  43. A. M. Prentice, “Obesity in emerging nations: evolutionary origins and the impact of a rapid nutrition transition,” Nestle Nutrition Workshop Series: Pediatric Program, vol. 63, pp. 47–57, 2009. View at: Publisher Site | Google Scholar
  44. M. Konner and S. Boyd Eaton, “Paleolithic nutrition: twenty-five years later,” Nutrition in Clinical Practice, vol. 25, no. 6, pp. 594–602, 2010. View at: Publisher Site | Google Scholar
  45. K. R. Timpano, N. B. Schmidt, M. G. Wheaton, J. R. Wendland, and D. L. Murphy, “Consideration of the BDNF gene in relation to two phenotypes: hoarding and obesity,” Journal of Abnormal Psychology, vol. 120, no. 3, pp. 700–707, 2011. View at: Publisher Site | Google Scholar
  46. C. Church, S. Lee, E. A. L. Bagg et al., “A mouse model for the metabolic effects of the human fat mass and obesity associated FTO gene,” PLoS Genetics, vol. 5, no. 8, Article ID e1000599, 2009. View at: Publisher Site | Google Scholar
  47. C. Dina, D. Meyre, S. Gallina et al., “Variation in FTO contributes to childhood obesity and severe adult obesity,” Nature Genetics, vol. 39, no. 6, pp. 724–726, 2007. View at: Publisher Site | Google Scholar
  48. T. M. Frayling, N. J. Timpson, M. N. Weedon et al., “A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity,” Science, vol. 316, no. 5826, pp. 889–894, 2007. View at: Publisher Site | Google Scholar
  49. S. Ereqat, A. Nasereddin, S. Cauchi, K. Azmi, Z. Abdeen, and R. Amin, “Association of a common variant in TCF7L2 gene with type 2 diabetes mellitus in the Palestinian population,” Acta Diabetologica, vol. 47, no. 1, pp. S195–S198, 2010. View at: Publisher Site | Google Scholar
  50. M. M. Zaharna, A. A. Abed, and F. A. Sharif, “Calpain-10 gene polymorphism in type 2 diabetes mellitus patients in the gaza strip,” Medical Principles and Practice, vol. 19, no. 6, pp. 457–462, 2010. View at: Publisher Site | Google Scholar
  51. I. Ezzidi, N. Mtiraoui, R. Nemr et al., “Variants within the calpain-10 gene and relationships with type 2 diabetes (T2DM) and T2DM-related traits among Tunisian Arabs,” Diabetes and Metabolism, vol. 36, no. 5, pp. 357–362, 2010. View at: Publisher Site | Google Scholar
  52. S. Mehri, B. Baudin, S. Mahjoub et al., “Angiotensin-converting enzyme insertion/deletion gene polymorphism in a Tunisian healthy and acute myocardial infarction population,” Genetic Testing and Molecular Biomarkers, vol. 14, no. 1, pp. 85–91, 2010. View at: Publisher Site | Google Scholar
  53. T. P. They-They, K. Hamzi, M. T. Moutawafik, H. Bellayou, M. El Messal, and S. Nadifi, “Prevalence of angiotensin-converting enzyme, methylenetetrahydrofolate reductase, Factor v Leiden, prothrombin and apolipoprotein e gene polymorphisms in Morocco,” Annals of Human Biology, vol. 37, no. 6, pp. 767–777, 2010. View at: Publisher Site | Google Scholar
  54. M. Akra-Ismail, R. F. Makki, H. N. Chmaisse, A. Kazma, and N. K. Zgheib, “Association between angiotensin-converting enzyme insertion/deletion genetic polymorphism and hypertension in a sample of Lebanese patients,” Genetic Testing and Molecular Biomarkers, vol. 14, no. 6, pp. 787–792, 2010. View at: Publisher Site | Google Scholar
  55. R. Nemr, R. A. Salman, L. H. Jawad, E. A. Juma, S. H. Keleshian, and W. Y. Almawi, “Differential contribution of MTHFR C677T variant to the risk of diabetic nephropathy in Lebanese and Bahraini Arabs,” Clinical Chemistry and Laboratory Medicine, vol. 48, no. 8, pp. 1091–1094, 2010. View at: Publisher Site | Google Scholar
  56. K. K. Abu-Amero, C. A. Wyngaard, O. M. Al-Boudari, M. Kambouris, and N. Dzimiri, “Lack of association of lipoprotein lipase gene polymorphisms with coronary artery disease in the Saudi Arab population,” Archives of Pathology and Laboratory Medicine, vol. 127, no. 5, pp. 597–600, 2003. View at: Google Scholar
  57. K. K. Abu-Amero, O. M. Al-Boudari, G. H. Mohamed, and N. Dzimiri, “The Glu27 genotypes of the Beta2-adrenergic receptor are predictors for severe coronary artery disease,” BMC Medical Genetics, vol. 7, article 31, 2006. View at: Publisher Site | Google Scholar
  58. K. Shiwaku, A. Nogi, E. Anuurad et al., “Difficulty in losing weight by behavioral intervention for women with Trp64Arg polymorphism of the β3-adrenergic receptor gene,” International Journal of Obesity, vol. 27, no. 9, pp. 1028–1036, 2003. View at: Publisher Site | Google Scholar
  59. A. Memisoglu, F. B. Hu, S. E. Hankinson et al., “Interaction between a peroxisome proliferator-activated receptor γ gene polymorphism and dietary fat intake in relation to body mass,” Human Molecular Genetics, vol. 12, no. 22, pp. 2923–2929, 2003. View at: Publisher Site | Google Scholar
  60. J. Luan, P. O. Browne, A. H. Harding et al., “Evidence for gene-nutrient interaction at the PPARγ locus,” Diabetes, vol. 50, no. 3, pp. 686–689, 2001. View at: Google Scholar
  61. V. Lindi, U. Schwab, A. Louheranta et al., “Impact of the Pro12Ala polymorphism of the PPAR-γ2 gene on serum triacylglycerol response to n-3 fatty acid supplementation,” Molecular Genetics and Metabolism, vol. 79, no. 1, pp. 52–60, 2003. View at: Publisher Site | Google Scholar
  62. J. A. Moreno, J. López-Miranda, C. Marín et al., “The influence of the apolipoprotein E gene promoter (-219G/T) polymorphism on postprandial lipoprotein metabolism in young normolipemic males,” Journal of Lipid Research, vol. 44, no. 11, pp. 2059–2064, 2003. View at: Publisher Site | Google Scholar
  63. G. J. Petot, F. Traore, S. M. Debanne, A. J. Lerner, K. A. Smyth, and R. P. Friedland, “Interactions of apolipoprotein E genotype and dietary fat intake of healthy older persons during mid-adult life,” Metabolism, vol. 52, no. 3, pp. 279–281, 2003. View at: Publisher Site | Google Scholar
  64. B. J. Nicklas, R. E. Ferrell, L. B. Bunyard, D. M. Berman, K. E. Dennis, and A. P. Goldberg, “Effects of apolipoprotein E genotype on dietary-induced changes in high-density lipoprotein cholesterol in obese postmenopausal women,” Metabolism, vol. 51, no. 7, pp. 853–858, 2002. View at: Publisher Site | Google Scholar
  65. J. T. Bazzaz, M. Nazari, H. Nazem et al., “Apolipoprotein e gene polymorphism and total serum cholesterol level in Iranian population,” Journal of Postgraduate Medicine, vol. 56, no. 3, pp. 173–175, 2010. View at: Publisher Site | Google Scholar
  66. A. O. Akanji, C. G. Suresh, H. R. Fatania, R. Al-Radwan, and M. Zubaid, “Associations of apolipoprotein E polymorphism with low-density lipoprotein size and subfraction profiles in Arab patients with coronary heart disease,” Metabolism, vol. 56, no. 4, pp. 484–490, 2007. View at: Publisher Site | Google Scholar
  67. J. M. Ordovas, D. Corella, S. Demissie et al., “Dietary fat intake determines the effect of a common polymorphism in the hepatic lipase gene promoter on high-density lipoprotein metabolism: evidence of a strong dose effect in this gene-nutrient interaction in the Framingham study,” Circulation, vol. 106, no. 18, pp. 2315–2321, 2002. View at: Publisher Site | Google Scholar
  68. E. S. Tai, D. Corella, M. Deurenberg-Yap et al., “Dietary fat interacts with the -514C>T polymorphism in the hepatic lipase gene promoter on plasma lipid profiles in a Multiethnic Asian population: the 1998 Singapore National Health Survey,” Journal of Nutrition, vol. 133, no. 11, pp. 3399–3408, 2003. View at: Google Scholar
  69. L. S. Rozek, T. S. Hatsukami, R. J. Richter et al., “The correlation of paraoxonase (PON1) activity with lipid and lipoprotein levels differs with vascular disease status,” Journal of Lipid Research, vol. 46, no. 9, pp. 1888–1895, 2005. View at: Publisher Site | Google Scholar
  70. G. P. Jarvik, L. S. Rozek, V. H. Brophy et al., “Paraoxonase (PON1) phenotype is a better predictor of vascular disease than is PON1192 or PON155 genotype,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 20, no. 11, pp. 2441–2447, 2000. View at: Google Scholar
  71. B. Agachan, H. Yilmaz, Z. Karaali, and T. Isbir, “Paraoxonase 55 and 192 polymorphism and its relationship to serum paraoxonase activity and serum lipids in Turkish patients with non-insulin dependent diabetes mellitus,” Cell Biochemistry and Function, vol. 22, no. 3, pp. 163–168, 2004. View at: Publisher Site | Google Scholar
  72. L. G. Costa, A. Vitalone, T. B. Cole, and C. E. Furlong, “Modulation of paraoxonase (PON1) activity,” Biochemical Pharmacology, vol. 69, no. 4, pp. 541–550, 2005. View at: Publisher Site | Google Scholar
  73. I. Nabipour, M. Amiri, S. R. Imami et al., “The metabolic syndrome and nonfatal ischemic heart disease; a population-based study,” International Journal of Cardiology, vol. 118, no. 1, pp. 48–53, 2007. View at: Publisher Site | Google Scholar
  74. M. Nsour, Z. Mahfoud, M. N. Kanaan, and A. Balbeissi, “Prevalence and predictors of non-fatal myocardial infarction in Jordan,” Eastern Mediterranean Health Journal, vol. 14, no. 4, pp. 818–830, 2008. View at: Google Scholar
  75. M. M. Al-Nozha, M. R. Arafah, Y. Y. Al-Mazrou et al., “Coronary artery disease in Saudi Arabia,” Saudi Medical Journal, vol. 25, no. 9, pp. 1165–1171, 2004. View at: Google Scholar
  76. H. Ben Romdhane, R. Khaldi, A. Oueslati, and H. Skhiri, “Transition épidémiologique et transition alimentaire et nutritionnelle en Tunisie,” Options Méditerranéennes B, vol. 41, 2002. View at: Google Scholar
  77. A. Al-Jishi and P. Mohan, “Profile of stroke in Bahrain,” Neurosciences, vol. 5, no. 1, pp. 30–34, 2000. View at: Google Scholar
  78. A. A. Ahangar, S. B. A. Vaghefi, and M. Ramaezani, “Epidemiological evaluation of stroke in Babol, Northern Iran (2001–2003),” European Neurology, vol. 54, no. 2, pp. 93–97, 2005. View at: Publisher Site | Google Scholar
  79. N. U. A. M. A. Abdul-Ghaffar, M. R. El-Sonbaty, M. S. El-Din Abdul-Baky, A. A. Marafie, and A. M. Al-Said, “Stroke in Kuwait: a three-year prospective study,” Neuroepidemiology, vol. 16, no. 1, pp. 40–47, 1997. View at: Google Scholar
  80. K. Radhakrishnan, P. P. Ashok, R. Sridharan, and M. A. El-Mangoush, “Incidence and pattern of cerebrovascular diseases in Benghazi, Libya,” Journal of Neurology Neurosurgery and Psychiatry, vol. 49, no. 5, pp. 519–523, 1986. View at: Google Scholar
  81. W. M. Sweileh, A. F. Sawalha, S. M. Al-Aqad et al., “The epidemiology of stroke in northern palestine: a 1-year, hospital-based study,” Journal of Stroke and Cerebrovascular Diseases, vol. 17, no. 6, pp. 406–411, 2008. View at: Publisher Site | Google Scholar
  82. A. Hamad, A. Hamad, T. E. O. Sokrab, S. Momeni, B. Mesraoua, and A. Lingren, “Stroke in Qatar: a one-year, hospital-based study,” Journal of Stroke and Cerebrovascular Diseases, vol. 10, no. 5, pp. 236–241, 2001. View at: Publisher Site | Google Scholar
  83. S. Al-Rajeh, E. B. Larbi, O. Bademosi et al., “Stroke register: experience from the Eastern Province of Saudi Arabia,” Cerebrovascular Diseases, vol. 8, no. 2, pp. 86–89, 1998. View at: Publisher Site | Google Scholar
  84. A. Yahia-Berrouiguet, M. Benyoucef, K. Meguenni, and M. Brouri, “Prevalence of cardiovascular risk factors: a survey at Tlemcen (Algeria),” Medecine des Maladies Metaboliques, vol. 3, no. 3, pp. 313–319, 2009. View at: Publisher Site | Google Scholar
  85. F. I. Al-Zurba, “Latest studies clarify state of health in Bahrain,” Diabetes Voice, vol. 46, pp. 28–31, 2001. View at: Google Scholar
  86. M. M. Ibrahim, H. Rizk, L. J. Appel et al., “Hypertension prevalence, awareness, treatment, and control in Egypt: results from the Egyptian National Hypertension Project (NHP),” Hypertension, vol. 26, no. 6, pp. 886–890, 1995. View at: Google Scholar
  87. O. M. Galal, “The nutrition transition in Egypt: obesity, undernutrition and the food consumption context,” Public Health Nutrition, vol. 5, no. 1, pp. 141–148, 2002. View at: Publisher Site | Google Scholar
  88. N. Sarraf-Zadegan, M. Boshtam, S. Mostafavi, and M. Rafiei, “Prevalence of hypertension and associated risk factors in Isfahan, Islamic Republic of Iran,” Eastern Mediterranean Health Journal, vol. 5, no. 5, pp. 992–1001, 1999. View at: Google Scholar
  89. A. A. Haghdoost, B. Sadeghirad, and M. Rezazadehkermani, “Epidemiology and heterogeneity of hypertension in Iran: a systematic review,” Archives of Iranian Medicine, vol. 11, no. 4, pp. 444–452, 2008. View at: Google Scholar
  90. WHO, “STEPwise surveillance. Non-communicable diseases risk factors. STEPwise data from selected countries in the Eastern Mediterranean Region, 2003–2007,” 2007, View at: Google Scholar
  91. M. Zindah, A. Belbeisi, H. Walke, and A. H. Mokdad, “Obesity and diabetes in Jordan: findings from the behavioral risk factor surveillance system, 2004,” Preventing Chronic Disease, vol. 5, pp. 1–8, 2008. View at: Google Scholar
  92. A.-M. Sibai, O. Obeid, M. Batal, N. Adra, D. E. Khoury, and N. Hwalla, “Prevalence and correlates of metabolic syndrome in an adult Lebanese population,” CVD Prevention and Control, vol. 3, no. 2, pp. 83–90, 2008. View at: Publisher Site | Google Scholar
  93. M. A. Tazi, S. Abir-Khalil, N. Chaouki et al., “Prevalence of the main cardiovascular risk factors in Morocco: results of a National Survey, 2000,” Journal of Hypertension, vol. 21, no. 5, pp. 897–903, 2003. View at: Publisher Site | Google Scholar
  94. A. A. Hasab, A. Jaffer, and Z. Hallaj, “Blood pressure patterns among the Omani population,” Eastern Mediterranean Health Journal, vol. 5, no. 1, pp. 46–54, 1999. View at: Google Scholar
  95. H. F. Abdul-Rahim, G. Holmboe-Ottesen, L. C. M. Stene et al., “Obesity in a rural and an urban Palestinian West Bank population,” International Journal of Obesity, vol. 27, no. 1, pp. 140–146, 2003. View at: Publisher Site | Google Scholar
  96. A. Bener, J. Al-Suwaidi, K. Al-Jaber, S. Al-Marri, M. H. Dagash, and I. E. Elbagi, “The prevalence of hypertension and its associated risk factors in a newly developed country,” Saudi Medical Journal, vol. 25, no. 7, pp. 918–922, 2004. View at: Google Scholar
  97. M. M. Al-Nozha, M. Abdullah, M. R. Arafah et al., “Hypertension in Saudi Arabia,” Saudi Medical Journal, vol. 28, no. 1, pp. 77–84, 2007. View at: Google Scholar
  98. W. Maziak, S. Rastam, F. Mzayek, K. D. Ward, T. Eissenberg, and U. Keil, “Cardiovascular health among adults in Syria: a model from developing countries,” Annals of Epidemiology, vol. 17, no. 9, pp. 713–720, 2007. View at: Publisher Site | Google Scholar
  99. H. M. Sonmez, O. Basak, C. Camci et al., “The epidemiology of elevated blood pressure as an estimate for hypertension in Aydin, Turkey,” Journal of Human Hypertension, vol. 13, no. 6, pp. 399–404, 1999. View at: Google Scholar
  100. L. M. Baynouna, A. D. Revel, N. J. Nagelkerke et al., “High prevalence of the cardiovascular risk factors in Al-Ain, United Arab Emirates. An emerging health care priority,” Saudi Medical Journal, vol. 29, no. 8, pp. 1173–1178, 2008. View at: Google Scholar
  101. A. A. Gunaid and A. M. Assabri, “Prevalence of type 2 diabetes and other cardiovascular risk factors in a semirural area in Yemen,” La Revue de Santé de la Méditerranée Orientale, vol. 14, no. 1, pp. 42–56, 2008. View at: Google Scholar
  102. B. Motlagh, M. O'Donnell, and S. Yusuf, “Prevalence of cardiovascular risk factors in the middle east: a systematic review,” European Journal of Cardiovascular Prevention and Rehabilitation, vol. 16, no. 3, pp. 268–280, 2009. View at: Publisher Site | Google Scholar
  103. A. Mehio Sibai, L. Nasreddine, A. H. Mokdad, N. Adra, M. Tabet, and N. Hwalla, “Nutrition transition and cardiovascular disease risk factors in Middle East and North Africa countries: reviewing the evidence,” Annals of Nutrition and Metabolism, vol. 57, no. 3-4, pp. 193–203, 2010. View at: Publisher Site | Google Scholar
  104. Y. Khader, A. Bateiha, M. El-Khateeb, A. Al-Shaikh, and K. Ajlouni, “High prevalence of the metabolic syndrome among Northern Jordanians,” Journal of Diabetes and Its Complications, vol. 21, no. 4, pp. 214–219, 2007. View at: Publisher Site | Google Scholar
  105. I. Al Rashdan and Y. Al Nesef, “Prevalence of overweight, obesity, and metabolic syndrome among adult Kuwaitis: results from community-based national survey,” Angiology, vol. 61, no. 1, pp. 42–48, 2010. View at: Publisher Site | Google Scholar
  106. M. Rguibi and R. Belahsen, “Metabolic syndrome among Moroccan Sahraoui adult women,” American Journal of Human Biology, vol. 16, no. 5, pp. 598–601, 2004. View at: Publisher Site | Google Scholar
  107. J. A. Al-Lawati and P. Jousilahti, “Prevalence of metabolic syndrome in Oman using the International Diabetes Federation's criteria,” Saudi Medical Journal, vol. 27, no. 12, pp. 1925–1926, 2006. View at: Google Scholar
  108. M. Musallam, A. Bener, M. Zirie et al., “Metabolic syndrome and its components among Qatari population,” International Journal of Food Safety, Nutrition and Public Health, vol. 1, no. 1, pp. 88–102, 2008. View at: Google Scholar
  109. A. Bener, M. Zirie, M. Musallam, Y. S. Khader, and A. O. Al-Hamaq, “Prevalence of metabolic syndrome according to adult treatment panel III and international diabetes federation criteria: a population-based study,” Metabolic Syndrome and Related Disorders, vol. 7, no. 3, pp. 221–230, 2009. View at: Publisher Site | Google Scholar
  110. M. M. Al-Nozha, A. Al-Khadra, M. R. Arafah et al., “Metabolic syndrome in Saudi Arabia,” Saudi Medical Journal, vol. 26, no. 12, pp. 1918–1925, 2005. View at: Google Scholar
  111. R. Bouguerra, L. Ben Salem, H. Alberti et al., “Prevalence of metabolic abnormalities in the Tunisian adults: a population based study,” Diabetes and Metabolism, vol. 32, no. 3, pp. 215–221, 2006. View at: Publisher Site | Google Scholar
  112. M. Malik and S. A. Razig, “The prevalence of the metabolic syndrome among the multiethnic population of the United Arab Emirates: a report of a national survey,” Metabolic Syndrome and Related Disorders, vol. 6, no. 3, pp. 177–186, 2008. View at: Publisher Site | Google Scholar
  113. P. M. Kearney, M. Whelton, K. Reynolds, P. K. Whelton, and J. He, “Worldwide prevalence of hypertension: a systematic review,” Journal of Hypertension, vol. 22, no. 1, pp. 11–19, 2004. View at: Publisher Site | Google Scholar
  114. T. A. Gaziano, A. Bitton, S. Anand, S. Abrahams-Gessel, and A. Murphy, “Growing epidemic of coronary heart disease in low- and middle-income countries,” Current Problems in Cardiology, vol. 35, no. 2, pp. 72–115, 2010. View at: Publisher Site | Google Scholar
  115. R. M. Mabry, M. M. Reeves, E. G. Eakin, and N. Owen, “Gender differences in prevalence of the metabolic syndrome in Gulf Cooperation Council Countries: a systematic review,” Diabetic Medicine, vol. 27, no. 5, pp. 593–597, 2010. View at: Publisher Site | Google Scholar
  116. J. Tran, M. Mirzaei, L. Anderson, and S. R. Leeder, “The epidemiology of stroke in the Middle East and North Africa,” Journal of the Neurological Sciences, vol. 295, no. 1-2, pp. 38–40, 2010. View at: Publisher Site | Google Scholar
  117. G. P. Page, J. W. Edwards, S. Barnes, R. Weindruch, and D. B. Allison, “A design and statistical perspective on microarray gene expression studies in nutrition: the need for playful creativity and scientific hard-mindedness,” Nutrition, vol. 19, no. 11-12, pp. 997–1000, 2003. View at: Publisher Site | Google Scholar
  118. M. F. Fenech, “Dietary reference values of individual micronutrients and nutriomes for genome damage prevention: current status and a road map to the future,” American Journal of Clinical Nutrition, vol. 91, no. 5, pp. 1438S–1454S, 2010. View at: Publisher Site | Google Scholar
  119. S. Kimball, G. E. H. Fuleihan, and R. Vieth, “Vitamin D: a growing perspective,” Critical Reviews in Clinical Laboratory Sciences, vol. 45, no. 4, pp. 339–414, 2008. View at: Publisher Site | Google Scholar
  120. R. Chesney, “Metabolic bone disease,” in Nelson Textbook of Pediatrics, R. E. Behrman, R. Kliegman, and H. B. Jenson, Eds., pp. 2132–2138, WB Saunders, Philadelphia, Pa, USA, 16th edition, 2000. View at: Google Scholar
  121. S. Wang, “Epidemiology of vitamin D in health and disease,” Nutrition Research Reviews, vol. 22, no. 2, pp. 188–203, 2009. View at: Publisher Site | Google Scholar
  122. C. F. Garland, F. C. Garland, E. D. Gorham et al., “The role of vitamin D in cancer prevention,” American Journal of Public Health, vol. 96, no. 2, pp. 252–261, 2006. View at: Publisher Site | Google Scholar
  123. M. Janner, P. Ballinari, P. E. Mullis, and C. E. Flück, “High prevalence of vitamin D deficiency in children and adolescents with type 1 diabetes,” Swiss Medical Weekly, vol. 140, article w13091, 2010. View at: Google Scholar
  124. J. S. Adams and M. Hewison, “Update in vitamin D,” Journal of Clinical Endocrinology and Metabolism, vol. 95, no. 2, pp. 471–478, 2010. View at: Publisher Site | Google Scholar
  125. S. R. Kreiter, R. P. Schwartz, H. N. Kirkman, P. A. Charlton, A. S. Calikoglu, and M. L. Davenport, “Nutritional rickets in African American breast-fed infants,” Journal of Pediatrics, vol. 137, no. 2, pp. 153–157, 2000. View at: Publisher Site | Google Scholar
  126. N. G. Jablonski and G. Chaplin, “The evolution of human skin coloration,” Journal of Human Evolution, vol. 39, no. 1, pp. 57–106, 2000. View at: Publisher Site | Google Scholar
  127. P. Lee, J. R. Greenfield, M. J. Seibel, J. A. Eisman, and J. R. Center, “Adequacy of vitamin D replacement in severe deficiency is dependent on body mass index,” American Journal of Medicine, vol. 122, no. 11, pp. 1056–1060, 2009. View at: Publisher Site | Google Scholar
  128. M. H. Gannagé-Yared, G. Maalouf, S. Khalife et al., “Prevalence and predictors of vitamin D inadequacy amongst Lebanese osteoporotic women,” British Journal of Nutrition, vol. 101, no. 4, pp. 487–491, 2009. View at: Publisher Site | Google Scholar
  129. K. Holvik, H. E. Meyer, E. Haug, and L. Brunvand, “Prevalence and predictors of vitamin D deficiency in five immigrant groups living in Oslo, Norway: the Oslo immigrant health study,” European Journal of Clinical Nutrition, vol. 59, no. 1, pp. 57–63, 2005. View at: Publisher Site | Google Scholar
  130. G. I. Baroncelli, A. Bereket, M. El Kholy et al., “Rickets in the Middle East: role of environment and genetic predisposition,” Journal of Clinical Endocrinology and Metabolism, vol. 93, no. 5, pp. 1743–1750, 2008. View at: Publisher Site | Google Scholar
  131. S. K. Ames, K. J. Ellis, S. K. Gunn, K. C. Copeland, and S. A. Abrams, “Vitamin D receptor gene Fok1 polymorphism predicts calcium absorption and bone mineral density in children,” Journal of Bone and Mineral Research, vol. 14, no. 5, pp. 740–746, 1999. View at: Publisher Site | Google Scholar
  132. H. Arai, K. I. Miyamoto, Y. Taketani et al., “A vitamin D receptor gene polymorphism in the translation initiation codon: effect on protein activity and relation to bone mineral density in Japanese women,” Journal of Bone and Mineral Research, vol. 12, no. 6, pp. 915–921, 1997. View at: Publisher Site | Google Scholar
  133. C. D. Davis, “Vitamin D and cancer: current dilemmas and future research needs,” American Journal of Clinical Nutrition, vol. 88, no. 2, 2008. View at: Google Scholar
  134. M. A. Abdullah, H. S. Salhi, L. A. Bakry et al., “Adolescent rickets in Saudi Arabia: a rich and sunny country,” Journal of Pediatric Endocrinology and Metabolism, vol. 15, no. 7, pp. 1017–1025, 2002. View at: Google Scholar
  135. H. Arai, K. I. Miyamoto, M. Yoshida et al., “The polymorphism in the caudal-related homeodomain protein Cdx-2 binding element in the human vitamin D receptor gene,” Journal of Bone and Mineral Research, vol. 16, no. 7, pp. 1256–1264, 2001. View at: Google Scholar
  136. A. V. Krishnan, S. Swami, J. Moreno, R. B. Bhattacharyya, D. M. Peehl, and D. Feldman, “Potentiation of the growth-inhibitory effects of vitamin D in prostate cancer by genistein,” Nutrition Reviews, vol. 65, no. 8, pp. S121–123, 2007. View at: Google Scholar
  137. A. Ali, G. Fathy, H. Fathy, and N. Abd El-Ghaffar, “Epidemiology of iron deficiency anaemia: effect of physical growth in primary school children, the importance of hookworms,” International Journal of Academic Research, vol. 3, pp. 495–500, 2011. View at: Google Scholar
  138. W. Burke, G. Imperatore, and M. Reyes, “Iron deficiency and iron overload: effects of diet and genes,” Proceedings of the Nutrition Society, vol. 60, no. 1, pp. 73–80, 2001. View at: Google Scholar
  139. Chung and R. Wessling-Resnick, “Lessons learned from genetic and nutritional iron deficiencies,” Nutrition Reviews, vol. 62, no. 5, pp. 212–215, 2004. View at: Publisher Site | Google Scholar
  140. J. E. Levy, L. K. Montross, and N. C. Andrews, “Genes that modify the hemochromatosis phenotype in mice,” Journal of Clinical Investigation, vol. 105, no. 9, pp. 1209–1216, 2000. View at: Google Scholar
  141. L. B. Bailey and J. F. Gregory, “Folate metabolism and requirements,” Journal of Nutrition, vol. 129, no. 4, pp. 779–782, 1999. View at: Google Scholar
  142. S. W. Choi and J. B. Mason, “Folate and carcinogenesis: an integrated scheme,” Journal of Nutrition, vol. 130, no. 2, pp. 129–132, 2000. View at: Google Scholar
  143. M. Moussavi, R. Heidarpour, A. Aminorroaya, Z. Pournaghshband, and M. Amini, “Prevalence of vitamin D deficiency in Isfahani high school students in 2004,” Hormone Research, vol. 64, no. 3, pp. 144–148, 2005. View at: Publisher Site | Google Scholar
  144. A. Batieha, Y. Khader, H. Jaddou et al., “Vitamin D status in Jordan: dress style and gender discrepancies,” Annals of Nutrition and Metabolism, vol. 58, no. 1, pp. 10–18, 2011. View at: Publisher Site | Google Scholar
  145. G. El-Hajj Fuleihan, M. Nabulsi, M. Choucair et al., “Hypovitaminosis D in healthy schoolchildren,” Pediatrics, vol. 107, article E53, 2001. View at: Google Scholar
  146. G. El-Hajj Fuleihan, M. Nabulsi, H. Tamim et al., “Effect of vitamin D replacement on musculoskeletal parameters in school children: a randomized controlled trial,” The Journal of Clinical Endocrinology and Metabolism, vol. 91, no. 2, pp. 405–412, 2006. View at: Publisher Site | Google Scholar
  147. A. Arabi, R. El Rassi, and G. El-Hajj Fuleihan, “Hypovitaminosis D in developing countries-prevalence, risk factors and outcomes,” Nature Reviews Endocrinology, vol. 6, no. 10, pp. 550–561, 2010. View at: Publisher Site | Google Scholar
  148. A. M. Siddiqui and H. Z. Kamfar, “Prevalence of vitamin D deficiency rickets in adolescent school girls in Western region, Saudi Arabia,” Saudi Medical Journal, vol. 28, no. 3, pp. 441–444, 2007. View at: Google Scholar
  149. A. O. Musaiger, “Iron deficiency anaemia among children and pregnant women in the arab gulf countries: the need for action,” Nutrition and Health, vol. 16, no. 3, pp. 161–171, 2002. View at: Google Scholar
  150. K. Bagchi, “Iron deficiency anaemia—an old enemy,” La Revue de Santé de la Méditerranée Orientale, vol. 10, no. 6, pp. 754–760, 2004. View at: Google Scholar
  151. W. Y. Almawi, R. R. Finan, H. Tamim, J. L. Daccache, and N. Irani-Hakime, “Differences in the Frequency of the C677T Mutation in the Methylenetetrahydrofolate Reductase (MTHFR) Gene Among the Lebanese Population,” American Journal of Hematology, vol. 76, no. 1, pp. 85–87, 2004. View at: Publisher Site | Google Scholar
  152. A. M. T. Engbersen, D. G. Franken, G. H. J. Boers, E. M. B. Stevens, F. J. M. Trijbels, and H. J. Blom, “Thermolabile 5,10-methylenetetrahydrofolate reductase as a cause of mild hyperhomocysteinemia,” American Journal of Human Genetics, vol. 56, no. 1, pp. 142–150, 1995. View at: Google Scholar
  153. N. M. van der Put and H. J. Blom, “Neural tube defects and a disturbed folate dependent homocysteine metabolism,” European Journal of Obstetrics Gynecology and Reproductive Biology, vol. 92, no. 1, pp. 57–61, 2000. View at: Publisher Site | Google Scholar
  154. H. J. Huh, H. S. Chi, E. H. Shim, S. Jang, and C. J. Park, “Gene-nutrition interactions in coronary artery disease: correlation between the MTHFR C677T polymorphism and folate and homocysteine status in a Korean population,” Thrombosis Research, vol. 117, no. 5, pp. 501–506, 2006. View at: Publisher Site | Google Scholar
  155. J. C. Chambers, H. Ireland, E. Thompson et al., “Methylenetetrahydrofolate reductase 677 C→T mutation and coronary heart disease risk in UK Indian Asians,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 20, no. 11, pp. 2448–2452, 2000. View at: Google Scholar
  156. S. A. Ross and L. Poirier, “Proceedings of the Trans-HHS Workshop: diet, DNA methylation processes and health,” Journal of Nutrition, vol. 132, no. 8, 2002. View at: Google Scholar
  157. J. Ma, M. J. Stampfer, E. Giovannucci et al., “Methylenetetrahydrofolate reductase polymorsphism, dietary interactions, and risk of colorectal cancer,” Cancer Research, vol. 57, no. 6, pp. 1098–1102, 1997. View at: Google Scholar
  158. Z. Abdollahi, I. Elmadfa, A. Djazayeri et al., “Folate, vitamin B12 and homocysteine status in women of childbearing age: baseline data of folic acid wheat flour fortification in Iran,” Annals of Nutrition and Metabolism, vol. 53, no. 2, pp. 143–150, 2008. View at: Publisher Site | Google Scholar
  159. S. L. Tokgözoǧlu, M. Alikaşifoǧlu, I. Ünsal et al., “Methylene tetrahydrofolate reductase genotype and the risk and extent of coronary artery disease in a population with low plasma folate,” Heart, vol. 81, no. 5, pp. 518–522, 1999. View at: Google Scholar
  160. B. Christensen, P. Frosst, S. Lussier-Cacan et al., “Correlation of a common mutation in the methylenetetrahydrofolate reductase gene with plasma homocysteine in patients with premature coronary artery disease,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 17, no. 3, pp. 569–573, 1997. View at: Google Scholar
  161. A. H. Messika, D. N. Kaluski, E. Lev et al., “Nutrigenetic impact of daily folate intake on plasma homocysteine and folate levels in patients with different methylenetetrahydrofolate reductase genotypes,” European Journal of Cardiovascular Prevention and Rehabilitation, vol. 17, no. 6, pp. 701–705, 2010. View at: Publisher Site | Google Scholar
  162. A. Wilson, R. Platt, Q. Wu et al., “A common variant in methionine synthase reductase combined with low cobalamin (Vitamin B12) increases risk for spina bifida,” Molecular Genetics and Metabolism, vol. 67, no. 4, pp. 317–323, 1999. View at: Publisher Site | Google Scholar
  163. L. E. Cahill, B. Fontaine-Bisson, and A. El-Sohemy, “Functional genetic variants of glutathione S-transferase protect against serum ascorbic acid deficiency,” American Journal of Clinical Nutrition, vol. 90, no. 5, pp. 1411–1417, 2009. View at: Publisher Site | Google Scholar
  164. L. E. Cahill and A. El-Sohemy, “Haptoglobin genotype modifies the association between dietary vitamin C and serum ascorbic acid deficiency,” American Journal of Clinical Nutrition, vol. 92, no. 6, pp. 1494–1500, 2010. View at: Publisher Site | Google Scholar
  165. J. M. Zingg, A. Azzi, and M. Meydani, “Genetic polymorphisms as determinants for disease-preventive effects of vitamin E,” Nutrition Reviews, vol. 66, no. 7, pp. 406–414, 2008. View at: Publisher Site | Google Scholar
  166. M. C. Zillikens, J. B. J. Van Meurs, F. Rivadeneira et al., “Interactions between dietary vitamin E intake and SIRT1 genetic variation influence body mass index,” American Journal of Clinical Nutrition, vol. 91, no. 5, pp. 1387–1393, 2010. View at: Publisher Site | Google Scholar
  167. H. Hamamy and A. Alwan, “Genetic disorders and congenital abnormalities: strategies for reducing the burden in the Region,” Eastern Mediterranean Health Journal, vol. 3, no. 1, pp. 123–132, 1997. View at: Google Scholar

Copyright © 2012 Akl C. Fahed et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

More related articles

 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.